CN106728894A - A kind of pharmaceutical composition for preventing and treating keratitis - Google Patents

A kind of pharmaceutical composition for preventing and treating keratitis Download PDF

Info

Publication number
CN106728894A
CN106728894A CN201611133156.2A CN201611133156A CN106728894A CN 106728894 A CN106728894 A CN 106728894A CN 201611133156 A CN201611133156 A CN 201611133156A CN 106728894 A CN106728894 A CN 106728894A
Authority
CN
China
Prior art keywords
weight portion
pharmaceutical composition
weight
ethanol
percent concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611133156.2A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611133156.2A priority Critical patent/CN106728894A/en
Publication of CN106728894A publication Critical patent/CN106728894A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pharmaceutical composition of keratitis and preparation method thereof is prevented and treated the invention discloses a kind of, pharmaceutical composition of the present invention is with nail orchid, liana cuneate lespedeza herb with root, Strobilanthes aehobarbus W. W. Smith, scale leaf glycyrrhizin C, betulic acid, Corosolic acid as bulk drug, proportioning is formed, routinely various formulations can be made by preparation process, prevent and treat keratitis evident in efficacy.

Description

A kind of pharmaceutical composition for preventing and treating keratitis
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for preventing and treating keratitis and its preparation side Method.
Background technology
Keratitis belongs to the categories such as traditional Chinese medical science keratomalacia, ice screen flaw depth, dendritic keratitis, is blinding illness in eye, belongs to the common urgency of ophthalmology Severe, seeks its etiology and pathogenesis, seeks effective therapy and formula, is ophthalmology worker's problem demanding prompt solution.Heat, wind, void, the stasis of blood are The key pathological factor that keratitis occurs, through the whole story of disease, the paathogenic factor as keratitis disease development evolution process And pathologic basis.Wherein, heat, wind invasion and attack occur for keratitis Important cause of disease and initiating agent, healthy tendency virtual loss system keratitis hair Raw inherence basis with lapse to substantially, be also the reason for causing palindromia.Hemostasis is both important pathology product in the keratitis course of disease Thing, and be disease generation, development, the important pathology link for aggravating.Therefore, heat, wind, void, stasis of blood interaction is keratitis morbidity to suffer from The important pathogenesis, four both can individually cause a disease, and can influence each other again.Heat can be changed in for example ailment said due to cold or exposure enters；Interior fire is above scorching, thermoae can Raw wind；Heat is contained and crossed with cold and cool in addition, must be caused deficiency of qi and yin and be caused weakened body resistance；Knot, deficiency of qi and yin can cause the stasis of blood in burning hot；Hemostasis is long Bridle, strongly fragrant longization are hot, and heat toxin heals Sheng, and pathogenic feelings are further aggravated.Be thusly-formed vicious circle, cause aggravation, patient's condition it is touching, It is obstinate refractory, the basic pathogenesis as keratitis morbidity.Part tissue of eye unique structure, train of thought very abundant is also easy to produce hemostasis, the stasis of blood Stop in blood, not general rule bitterly, specific to eye, can behave as that ophthalmodynia, eye are swollen, eye is swollen, eye hemostasis etc.；Stop in hemostasis, blood it is unfavorable It is then water, can behave as ocular edema, above-mentioned symptom is the basic shape symptom of keratitis.Therefore, stop also to be keratitis in hemostasis One of pathological factor.Element is blood stasis constitution patient, or because of affection of exogenous wind-heat, chill, with the passing of time forms the stasis of blood because thermojunction, cold solidifying, phlegm gather； Or because of sick gas, blood, yin, yang virtual loss long, because void forms the stasis of blood.It can be seen that, hemostasis is pathological product important in keratitis course advancement. Hemostasis causes the state of an illness further to develop exacerbation once generation, if stagnation of blood stasis mesh median nexus, general rule bitterly, does not suffer from eye pain day It is acute；It is then water that blood is unfavorable, suffers from pupil eyeball muddiness oedema day very；Stagnation of blood stasis mesh network, qi-blood-body fluid can not on hold, mesh lose self-restraint And regard dusk；Hemostasis bridle and then changes heat long, and heat toxin heals Sheng, and pathogenic feelings are further aggravated.
Nail is blue：This product is the short stem calyx ridge orchid Sedirea subparishii of orchid family Calanthe plant（Tsi）E. A. Chr. the herb of [Hygrochilus subparishii Tsi].Whole year can adopt, using fresh herb.【Nature and flavor】Bitter；It is cool in nature.【Work( Can cure mainly】Clearing heat for calming endogenous wind.Main child convulsion wind.【Former phytomorph】Short stem calyx ridge is blue, perennial evergreen draft of growing nonparasitically upon another plant.Stem is short And tiltedly on, pleat phyllopodium is surrounded, bottom is grown thickly aerial root.Aerial root is sturdy and grow, bend, white, without hair.3-5 pieces of leaf, 2 row, slightly meat, Long Circle or round shape lanceolar long, 6-12cm long, 2-3.5cm wide, tip it is blunt or tiltedly and 2 it is shallow split, base portion is narrowed Stem is embraced, has linear slit cylindrarthrosis, middle arteries are obvious.Scape 1-4, it is born in basal part of stem axil；Raceme 5-17cm long, sparsely grow flower 4- More than 10；Petal piece oval, 7-12mm long, 3-9mm wide, tip blunt circle；Flower pistac；Sepal and petal are closely similar, long Ellipse, 18-20mm long, slightly the widest part 7-9mm wide, meat carry out, and have 7, arteries and veins, and the anxious point of tip, middle sepal is slightly wider, side sepal It is narrower with petal, the carinate wing of tool is helped in the sepal back side；Lip 3 splits, middle sliver meat, long and narrow circle, 8-10mm long, about 2mm wide, Has the 1 piece high gusset of about 1.5mm from base portion to tip, side sliver is upright, and semicircular edge has micro- tooth, has 1 piece of circular cone at mouth Shape corpus callosum；Elongation shape, is about 1cm, slightly arc, to extension；Stamen column length 13-15mm, has stamen shape wing, and rostellum elongation 2 is split, rostellum Handle tip expands；Stick to the pan circle.Capsule oblong, connecting handle is about 7cm.The month at florescence 5-6, fruiting period September.Record in the big diction of Chinese medicine Allusion quotation.
Liana cuneate lespedeza herb with root：It is Convolvulaceae white crane Calamus plant gray wool white crane rattan Argyreia osyrensis (Roth) The leaf of Choisy var.cinerea Hand.-Mazz. [lettsomia bella auct. Non C. B.Clarke] or Root.Ye Xia, autumn harvesting, dry；Root whole year can adopt, clean, section, dry.【Nature and flavor】It is puckery；Temperature.【Indication】Inducing astrigency is consolidated It is de-；Astringe the lung；Hemostasis.Main rush down prolapse of the anus for a long time；The prolapse of uterus；Deficiency syndrome of the lung cough and asthma；Menorrhalgia；Traumatism and bleeding.【Proterties】The many shrinkages of leaf are broken It is broken.It is in avette or wealthy avette, 6-12cm long, 3.5-11cm wide after complete leaf flattening, the sharp point of tip, base portion is heart-shaped, and upper surface is close By the pubescence grey long of tool warty base portion, the grey pubescence that lower surface is curled；Petiole 3-3.5cm long, close that pubescence is crimped by grey, tool Groove, gas is micro-, mildly bitter flavor.【Former phytomorph】Gray wool white crane rattan climbing shrub.Stem cylinder, it is close by white or with grey or light Brown fine hair.Single leaf alternate；Petiole 3-7.5cm long, it is close that pubescence is crimped by grey, have groove；Blade width egg shape to subcircular, 6- long 12cm, 3.5-11cm wide, the sharp point of tip, base portion are heart-shaped, above the close grey pubescence long of lying prostrate for being had a warty base portion, the back side is close by pole It is close and crimp grey pubescence.Inflorescence is gathered into head, flower stockless or nearly stockless；Total bennet, bract and sepal outside are by fine hair； Corolla tubulose is bell, pink, and limb deep 5 splits, and sliver is narrow avette, with close by white pubescence in valve；Stamen and style stretch out；Flower Silk base portion expands, by hair；Ovary without hair, Room 2.It is really spherical, it is red, the sepal to increase is wrapped, sepal inner face is red.2, seed Or 1, it is bordering on without hair.Autumn at florescence, winter.Record in dictionary of medicinal plant.
Strobilanthes aehobarbus W. W. Smith：It is Acanthaceae kalimeris platymiscium capillary copper purple cloud dish Strobilanthes aehobarbus W. W. The root and leaf of Smith.Root, leaf whole year can adopt, and clean, and dry.【Nature and flavor】It is lightly seasoned；Slight bitter；It is mild-natured.【Return through】The heart；Lung；Liver Through.【Indication】Clearing liver dampness removing；Promoting blood circulation to remove blood stasis.Main jaundice with damp-heat pathogen；Red eye, swell pain；Irregular menstruation；Postpartum abdominal pain.【Former plant Form】The capillary copper purple cloud perennial shrub shape draft of dish, about 1m high.Stem is upright, multi-branched, the prismatic of top four, and section expands, flat It is flat, it is close by brown color undercoat, it is miscellaneous to have white pubescence long, it is especially close with browse hair.Single leaf opposite；There is handle；Blade oval or ovum Shape, tip is tapering, and base portion is slightly asymmetric, blunt circle or heart, and side tool dredges crenation, above sunlight green, below mulberry, two sides quilt Brown color undercoat and white become mildewed, in blueness after hair such as wiping is de- on branches and leaves.Spike basidixed or axillary；Bract is lobate；Calyx 5 Split；Flower purple；Corolla tubular, tip 5 splits, two lips；Stamen 4, the last two, filigree base portion has river film quality to be connected, and corolla inner face has 2 Row undercoat.Capsule.There is 4, seed.Record in dictionary of medicinal plant.
Scale leaf glycyrrhizin C（Glepidotin C）：CAS 87440-56-0, molecular formula C20H20O5, molecular weight 340.38. 【Pharmacological action】Antibacterial.【Ingredient origin】Pulse family American licorice Glycyrrhiza lepidota.
Betulic acid（Betulinic acid）：CAS 472-15-1, molecular formula C30H48O3, molecular weight 456.71.【It is raw Thing activity】It is antitumor（W256）.【Ingredient origin】Date Ziziphus jujuba, tree-like cuckoo Rhododendron Arboreum, camplotheca acuminata Camptotheca acuminata.
Corosolic acid（Corosolic acid）：CAS 4547-24-4, molecular formula C30H48O4, molecular weight 472.70.【Into Divide source】Red chopsticks Chamaenerion angustifolium [Syn.Epilobium angustifolium], three leaf rat-tails Careless Salvia trijuga.
3 chemical constitutions of bulk drug：
Scale leaf glycyrrhizin C（Glepidotin C）
Betulic acid（Betulinic acid）Corosolic acid（Corosolic acid）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided it is a kind of effectively prevent and treat keratitis pharmaceutical composition and Its preparation method.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for being made the bulk drug of the pharmaceutical composition for preventing and treating keratitis be：
Nail orchid 530-540 weight portion liana cuneate lespedeza herb with root 525-530 weight portion Strobilanthes aehobarbus W. W. Smith 510-520 weight portion scale leafs are sweet Careless element C15-20 weight portion betulic acid 10-13 weight portion Corosolic acid 6-9 weight portions.
The pharmaceutical composition for preventing and treating keratitis is preferably used in, is made up of the bulk drug of following weight portion：
The nail orchid weight portion scale leaf glycyrrhizin C18 weight portions of 535 528 weight portion Strobilanthes aehobarbus W. W. Smith of weight portion liana cuneate lespedeza herb with root 515 The weight portion of 12 weight portion Corosolic acid of betulic acid 8.
A kind of pharmaceutical composition for preventing and treating keratitis, it is characterised in that pharmaceutical composition can be using the routine side of galenic pharmacy Method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for preventing and treating keratitis, it is characterised in that pharmaceutical composition is anti-with what chemical drugs or Chinese medicine were constituted Control keratitis medicine.
A kind of preparation method of the pharmaceutical composition for preventing and treating keratitis, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Nail orchid 530-540 weight portion liana cuneate lespedeza herb with root 525-530 weight portions 13 years Flower 510-520 weight portion scale leaf glycyrrhizin C15-20 weight portion betulic acid 10-13 weight portion Corosolic acid 6-9 weight portions；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Strobilanthes aehobarbus W. W. Smith, nail orchid, scale leaf glycyrrhizin C, betulic acid, koroso are taken by bulk drug proportioning Acid, mixes, and with the ethanol of weight percent concentration 24% as solvent, is taken in 25 DEG C of temperature extractions, and extraction time is 19 times, is carried every time The time is taken for 13 hours, each solvent load is 27.5 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extracts Liquid A reclaims ethanol, is concentrated into relative density 1.02, filters, and liquid is first washed with water by DM133 large pore resin absorption columns, DM133 large pore resin absorption columns are eluted with the ethanol solution of weight percent concentration 17% again, the second of weight percent concentration 17% is collected Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 44% as solvent, heating and refluxing extraction 12 times is carried every time The time is taken for 0.8 hour, each solvent load is 40.5 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, extract solution B Ethanol is reclaimed, relative density 1.13 is concentrated into, filtered, liquid is first washed with water by LK07 large pore resin absorption columns, then with again Amount percent concentration 66% ethanol solution wash-out LK07 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 66% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for preventing and treating keratitis, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：The nail orchid weight of 535 528 weight portion Strobilanthes aehobarbus W. W. Smith of weight portion liana cuneate lespedeza herb with root 515 The weight portion of 12 weight portion Corosolic acid of amount part scale leaf glycyrrhizin C18 weight portions betulic acid 8；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Strobilanthes aehobarbus W. W. Smith, nail orchid, scale leaf glycyrrhizin C, betulic acid, koroso are taken by bulk drug proportioning Acid, mixes, and with the ethanol of weight percent concentration 24% as solvent, is taken in 25 DEG C of temperature extractions, and extraction time is 19 times, is carried every time The time is taken for 13 hours, each solvent load is 27.5 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extracts Liquid A reclaims ethanol, is concentrated into relative density 1.02, filters, and liquid is first washed with water by DM133 large pore resin absorption columns, DM133 large pore resin absorption columns are eluted with the ethanol solution of weight percent concentration 17% again, the second of weight percent concentration 17% is collected Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 44% as solvent, heating and refluxing extraction 12 times is carried every time The time is taken for 0.8 hour, each solvent load is 40.5 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, extract solution B Ethanol is reclaimed, relative density 1.13 is concentrated into, filtered, liquid is first washed with water by LK07 large pore resin absorption columns, then with again Amount percent concentration 66% ethanol solution wash-out LK07 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 66% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for preventing and treating keratitis, it is characterised in that pharmaceutical composition can use preparation Conventional method prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for preventing and treating keratitis, it is characterised in that pharmaceutical composition and chemical drugs or in Medicine composition prevents and treats keratitis medicine.
It is notable that pharmaceutical composition prevents and treats keratitis effect.
Specific embodiment
Embodiment 1：Prevent and treat pharmaceutical composition of keratitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of keratitis be：Nail orchid 535g liana cuneate lespedeza herb with root 528g Strobilanthes aehobarbus W. W. Smith 515g scale leaf glycyrrhizin C18g betulic acid 12g Corosolic acids 8g；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Strobilanthes aehobarbus W. W. Smith, nail orchid, scale leaf glycyrrhizin C, betulic acid, koroso are taken by bulk drug proportioning Acid, mixes, and with the ethanol of weight percent concentration 24% as solvent, is taken in 25 DEG C of temperature extractions, and extraction time is 19 times, is carried every time The time is taken for 13 hours, each solvent load is 27.5 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extracts Liquid A reclaims ethanol, is concentrated into relative density 1.02, filters, and liquid is first washed with water by DM133 large pore resin absorption columns, DM133 large pore resin absorption columns are eluted with the ethanol solution of weight percent concentration 17% again, the second of weight percent concentration 17% is collected Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 44% as solvent, heating and refluxing extraction 12 times is carried every time The time is taken for 0.8 hour, each solvent load is 40.5 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, extract solution B Ethanol is reclaimed, relative density 1.13 is concentrated into, filtered, liquid is first washed with water by LK07 large pore resin absorption columns, then with again Amount percent concentration 66% ethanol solution wash-out LK07 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 66% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Prevent and treat pharmaceutical composition of keratitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of keratitis be：Nail orchid 530g liana cuneate lespedeza herb with root 530g Strobilanthes aehobarbus W. W. Smith 510g scale leaf glycyrrhizin C20g betulic acid 10g Corosolic acids 9g；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Strobilanthes aehobarbus W. W. Smith, nail orchid, scale leaf glycyrrhizin C, betulic acid, koroso are taken by bulk drug proportioning Acid, mixes, and with the ethanol of weight percent concentration 24% as solvent, is taken in 25 DEG C of temperature extractions, and extraction time is 19 times, is carried every time The time is taken for 13 hours, each solvent load is 27.5 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extracts Liquid A reclaims ethanol, is concentrated into relative density 1.02, filters, and liquid is first washed with water by DM133 large pore resin absorption columns, DM133 large pore resin absorption columns are eluted with the ethanol solution of weight percent concentration 17% again, the second of weight percent concentration 17% is collected Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 44% as solvent, heating and refluxing extraction 12 times is carried every time The time is taken for 0.8 hour, each solvent load is 40.5 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, extract solution B Ethanol is reclaimed, relative density 1.13 is concentrated into, filtered, liquid is first washed with water by LK07 large pore resin absorption columns, then with again Amount percent concentration 66% ethanol solution wash-out LK07 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 66% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Prevent and treat pharmaceutical composition of keratitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of keratitis be：Nail orchid 540g liana cuneate lespedeza herb with root 525g Strobilanthes aehobarbus W. W. Smith 520g scale leaf glycyrrhizin C15g betulic acid 13g Corosolic acids 6g；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Strobilanthes aehobarbus W. W. Smith, nail orchid, scale leaf glycyrrhizin C, betulic acid, koroso are taken by bulk drug proportioning Acid, mixes, and with the ethanol of weight percent concentration 24% as solvent, is taken in 25 DEG C of temperature extractions, and extraction time is 19 times, is carried every time The time is taken for 13 hours, each solvent load is 27.5 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extracts Liquid A reclaims ethanol, is concentrated into relative density 1.02, filters, and liquid is first washed with water by DM133 large pore resin absorption columns, DM133 large pore resin absorption columns are eluted with the ethanol solution of weight percent concentration 17% again, the second of weight percent concentration 17% is collected Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 44% as solvent, heating and refluxing extraction 12 times is carried every time The time is taken for 0.8 hour, each solvent load is 40.5 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, extract solution B Ethanol is reclaimed, relative density 1.13 is concentrated into, filtered, liquid is first washed with water by LK07 large pore resin absorption columns, then with again Amount percent concentration 66% ethanol solution wash-out LK07 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 66% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 520g of Example 1, adds starch 530g, mixes, and granulation is dried, plus microcrystalline cellulose 240g, stearic Sour magnesium 25g, mixes, and is pressed into 5000, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 380g of Example 2, adds starch 420g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid Magnesium, mixes, and encapsulated 3000, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 270g water-baths and boil molten, add the pharmaceutical composition 13g of embodiment 3, fully stir Mix uniform, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 3 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.0cm away from liquid level, and drop speed is optimum condition with every point 46 drop, and the cold of dripping pill surface is blotted with cotton Solidifying agent, obtains final product medicament composition dropping pills.
Experimental example 1：Prevent and treat the experimental study of keratitis
1 clinical data
1.1 diagnostic criteria
With reference to State Administration of Traditional Chinese Medicine《Chinese medical disease Standardization of diagnosis and curative effect》The diagnosis mark of middle dendritic keratitis (viral keratitis) It is accurate:(1) dry and astringent photophobia, shouting pain is shed tears, blurred vision；(2) often there is the inducement such as affection of exogenous wind-heat or eye wound；(3) cornea asterism Guizhou Province hinders, poly- or scattered, or joins together in flakes, shape such as branch or map shape, ciliary hyperemia；(4) diseased region corneal sensation is gone down；（5） Corneal fluorescein stained positive.
1.2 physical data
Observation case totally 25 (28), is this city hospital outpatient patient.Man 13, female 12；Age 12-70 Sui；Morbidity - 1 year 3 days time；Simple eye ill 22, eyes are ill 3；Pathogenic factor:There are trauma history 6, history of operation 4, facial scar rash Infection 6, reason is not clear 9.Form ulcer person 5；Corneal fluorescein dyeing is the positive；Cornea has water under slit-lamp Swollen, 4 companions see keratic precipitates (Kp).
2 treatment methods
All cases give pharmaceutical composition（The pharmaceutical composition of embodiment 1）Decocting liquid hot compression therapy.Plus-minus:Affection of exogenous wind-heat person add Schizonepeta, the capsule of weeping forsythia, honeysuckle；Dampness-heat of liver channel person adds felwort, Huang Fen；Dominance of heat in the interior person adds Radix Isatidis, folium isatidis, Chinese violet； Flaring up of deficient fire person adds golden cypress, chrysanthemum.Add medicine to the 1500mL that adds water, and first decocts with high heat to water boiling, then with being cooked by slow fire 20 minutes, filter to take Liquid；Then method is gone up for another example takes concoction 1 time, it is standby after 2 liquids are mixed.Used time take thousand net towels be dipped in it is wet in liquid Thoroughly, (it is advisable so that patient is tolerable) when being then screwed onto humidity, proper temperature, spreads on and suffer from eye, each 20-30 minutes, daily 3-4 It is secondary.It is within 2 weeks 1 course for the treatment of.1 course for the treatment of does not heal person, lower 1 course for the treatment of of row again of interval 3 days, and 2 courses for the treatment of are treated altogether.
3 criterions of therapeutical effect and treatment results
3.1 criterions of therapeutical effect
With reference to State Administration of Traditional Chinese Medicine《Chinese medical disease Standardization of diagnosis and curative effect》The curative effect of dendritic keratitis (viral keratitis) in river Standard combination clinical setting is drafted.Cure:Corneal irritation disappears, and infiltration absorbs, ulcer reparation, and corneal fluorescein dyeing is cloudy Property, corneal edema disappears under slit-lamp, and Kp disappears or leave a small amount of pigmentosa Kp, and vision restoration is normal or rebound significantly.Take a turn for the better: Corneal irritation mitigates, and infiltration substantially absorbs, and ulcer is substantially repaired, corneal fluorescein dyeing weakly positive, cornea under slit-lamp Oedema mitigates but does not recover normal, and eyesight increases.It is invalid:Corneal symptoms are not improved or aggravate after treatment, and cornea is glimmering Light element stained positive.
3.2 treatment results
Cure 16, take a turn for the better 10, invalid 2, total effective rate is 92.86%.

Claims (8)

1. a kind of pharmaceutical composition for preventing and treating keratitis, it is characterised in that be made the composition and weight of the bulk drug of the pharmaceutical composition Measuring part is：
Nail orchid 530-540 weight portion liana cuneate lespedeza herb with root 525-530 weight portion Strobilanthes aehobarbus W. W. Smith 510-520 weight portion scale leafs are sweet Careless element C15-20 weight portion betulic acid 10-13 weight portion Corosolic acid 6-9 weight portions.
2. a kind of pharmaceutical composition for preventing and treating keratitis according to claim 1, it is characterised in that be made the pharmaceutical composition Bulk drug composition and weight portion be：
The nail orchid weight portion scale leaf glycyrrhizin C18 weight portions of 535 528 weight portion Strobilanthes aehobarbus W. W. Smith of weight portion liana cuneate lespedeza herb with root 515 The weight portion of 12 weight portion Corosolic acid of betulic acid 8.
3. a kind of pharmaceutical composition for preventing and treating keratitis according to claim 1, it is characterised in that pharmaceutical composition can be adopted Piece agent or capsule or dripping pill are prepared with the conventional method of galenic pharmacy.
4. a kind of pharmaceutical composition for preventing and treating keratitis according to claim 1, it is characterised in that pharmaceutical composition and chemistry What medicine or Chinese medicine were constituted prevents and treats keratitis medicine.
5. a kind of preparation method of the pharmaceutical composition for preventing and treating keratitis, it is characterised in that prepare as follows：
Nail orchid 530-540 weight portion liana cuneate lespedeza herb with root 525-530 weight portion Strobilanthes aehobarbus W. W. Smith 510-520 weight portion scale leafs are sweet Careless element C15-20 weight portion betulic acid 10-13 weight portion Corosolic acid 6-9 weight portions；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Strobilanthes aehobarbus W. W. Smith, nail orchid, scale leaf glycyrrhizin C, betulic acid, koroso are taken by bulk drug proportioning Acid, mixes, and with the ethanol of weight percent concentration 24% as solvent, is taken in 25 DEG C of temperature extractions, and extraction time is 19 times, is carried every time The time is taken for 13 hours, each solvent load is 27.5 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extracts Liquid A reclaims ethanol, is concentrated into relative density 1.02, filters, and liquid is first washed with water by DM133 large pore resin absorption columns, DM133 large pore resin absorption columns are eluted with the ethanol solution of weight percent concentration 17% again, the second of weight percent concentration 17% is collected Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 44% as solvent, heating and refluxing extraction 12 times is carried every time The time is taken for 0.8 hour, each solvent load is 40.5 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, extract solution B Ethanol is reclaimed, relative density 1.13 is concentrated into, filtered, liquid is first washed with water by LK07 large pore resin absorption columns, then with again Amount percent concentration 66% ethanol solution wash-out LK07 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 66% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for preventing and treating keratitis according to claim 5, it is characterised in that by as follows It is prepared by step：
The nail orchid weight portion scale leaf glycyrrhizin C18 weight portions of 535 528 weight portion Strobilanthes aehobarbus W. W. Smith of weight portion liana cuneate lespedeza herb with root 515 The weight portion of 12 weight portion Corosolic acid of betulic acid 8；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Strobilanthes aehobarbus W. W. Smith, nail orchid, scale leaf glycyrrhizin C, betulic acid, koroso are taken by bulk drug proportioning Acid, mixes, and with the ethanol of weight percent concentration 24% as solvent, is taken in 25 DEG C of temperature extractions, and extraction time is 19 times, is carried every time The time is taken for 13 hours, each solvent load is 27.5 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extracts Liquid A reclaims ethanol, is concentrated into relative density 1.02, filters, and liquid is first washed with water by DM133 large pore resin absorption columns, DM133 large pore resin absorption columns are eluted with the ethanol solution of weight percent concentration 17% again, the second of weight percent concentration 17% is collected Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 44% as solvent, heating and refluxing extraction 12 times is carried every time The time is taken for 0.8 hour, each solvent load is 40.5 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, extract solution B Ethanol is reclaimed, relative density 1.13 is concentrated into, filtered, liquid is first washed with water by LK07 large pore resin absorption columns, then with again Amount percent concentration 66% ethanol solution wash-out LK07 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 66% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for preventing and treating keratitis according to claim 5, it is characterised in that medicine group Compound can prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
8. a kind of preparation method of the pharmaceutical composition for preventing and treating keratitis according to claim 5, it is characterised in that medicine group Compound prevents and treats keratitis medicine with chemical drugs or Chinese medicine composition.
CN201611133156.2A 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating keratitis Withdrawn CN106728894A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611133156.2A CN106728894A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating keratitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611133156.2A CN106728894A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating keratitis

Publications (1)

Publication Number Publication Date
CN106728894A true CN106728894A (en) 2017-05-31

Family

ID=58875023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611133156.2A Withdrawn CN106728894A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating keratitis

Country Status (1)

Country Link
CN (1) CN106728894A (en)

Similar Documents

Publication Publication Date Title
CN102755596B (en) Traditional Chinese medicine for treating phlegm-dampness hyperplasia of mammary glands and preparation method thereof
CN102614413B (en) Chinese medicinal composition for treating sinusitis in children and preparation method thereof
CN103495072B (en) Traditional Chinese medicine composition treating bronchiectasia disease and preparation method thereof
CN105412697A (en) Herba eupatorii oral liquid for clearing heat and removing dampness, and protecting liver and gallbladder and preparation method of oral liquid
CN103860787B (en) The external application Chinese medicine of the treatment acne containing flower clam effective ingredient
CN102327404A (en) Traditional Chinese medicine preparation for treating male venereal diseases
CN106728894A (en) A kind of pharmaceutical composition for preventing and treating keratitis
CN101249245A (en) Medicament for curing esophagus cancer and cardiac cancer
CN104689283A (en) Medicine for treatment of spleen insufficiency damp-aggregating type chloasma and preparation method thereof
CN106668125A (en) Pharmaceutical composition for treating optic atrophy and preparation method of pharmaceutical composition
CN106822206A (en) It is a kind of to treat pharmaceutical composition of neurodermatitis and preparation method thereof
CN106581122A (en) Pharmaceutical composition for treating acute cervicitis
CN106692235A (en) Pharmaceutical composition for preventing and treating keratitis
CN106727861A (en) It is a kind of to treat pharmaceutical composition of parotitis and preparation method thereof
CN105250713A (en) Medicine for nursing and treating excessive-noxious-heat-type acute mastitis and preparing method
CN106727859A (en) It is a kind of to treat pharmaceutical composition of pharyngitis and preparation method thereof
CN105726883A (en) Traditional Chinese medicine tea drink for preventing hypertension
CN105943646A (en) Multifunctional traditional Chinese medicine liquid capable of achieving disinfection, killing germs and stopping bleeding
CN105497732A (en) Lacrimal duct irrigation fluid for nursing of infantile congenital lacrimal duct obstruction
CN104758553A (en) Traditional Chinese medicine for treating arrhythmia
CN105362511B (en) A kind of Chinese medicine composition and its preparation for treating fibroid
CN105148118B (en) A kind of Chinese medicine composition medicament and preparation method thereof for treating xerophthalmia
CN106539838A (en) Prevent and treat the pharmaceutical composition of neurodermatitis
CN106692512A (en) Pharmaceutical composition capable of preventing and treating uterine fibroid
CN106581095A (en) Medicinal composition for treating neurodermatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170531

WW01 Invention patent application withdrawn after publication